Hansoh Pharmaceutical Group (HKG:3692) said the second biologics license application or BLA of its antibody drug XINYUE (Inebilizumab Injection) was accepted by the National Medical Products Administration or NMPA, a Tuesday bourse filing said.
The drug is a targeted CD19 B cell-depleting antibody and is used to treat immunoglobulin G4-related disease, a chronic inflammatory condition.
In May 2019, Viela Bio granted the group the exclusive license to develop and commercialize the drug in China, Hong Kong, and Macau.
NMPA approved the launch of the drug in China in 2022, while the drug was also included in the national reimbursement drug list in 2023, a status that was renewed in November 2024.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。